Companies: 10,795·Total market cap: $144.5T
Astria Therapeutics, Inc.

Astria Therapeutics, Inc.

ATXSNASDAQHealthcare
$12.58
+$0.00(+0.00%)
Market Cap$718127262
P/E Ratio—
52W High$13.29
52W Low$3.555
SEC Filings

Astria Therapeutics, Inc. (ATXS) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001454789 · ATXS · NASDAQ · as of Jun 8, 2026

Filing snapshot

628
Total Filings
SCHEDULE 13G/A
Latest Form
2026-02-17
Most Recent
2015
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001454789 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2025-03-11
Fiscal Year End
Mar 11, 2025
Accession No.
0001410578-25-000309
Primary Document
atxs-20241231x10k.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001454789 · Accession 0001410578-25-000309

Latest Key Filings

10-QQuarterly Report
10-Q
2025-11-12
View 10-Q on SEC
8-KCurrent Report
FORM 8-K
2026-01-23Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-12
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-02-09
View
15-12G15-12G
15-12G
2026-02-02
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-01-28
View
EFFECTEFFECT
EFFECT
2026-01-27
View
EFFECTEFFECT
EFFECT
2026-01-27
View
EFFECTEFFECT
EFFECT
2026-01-27
View
EFFECTEFFECT
EFFECT
2026-01-27
View
EFFECTEFFECT
EFFECT
2026-01-27
View
EFFECTEFFECT
EFFECT
2026-01-27
View
25-NSE/A25-NSE/A
25-NSE/A
2026-01-26
View
S-8 POSS-8 POS
S-8 POS
2026-01-23
View
S-8 POSS-8 POS
S-8 POS
2026-01-23
View
S-8 POSS-8 POS
S-8 POS
2026-01-23
View
Showing 1–15 of 443 filingsForm 4 / 144 hidden· 628 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001454789  |  Exchange: NASDAQ · Healthcare

Astria Therapeutics, Inc. (NASDAQ: ATXS) has submitted 628 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2015. As a Healthcare sector company with CIK 0001454789, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Astria Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Astria Therapeutics, Inc. 10-K was filed on 2025-03-11 for fiscal year ending 2025. Historical ATXS 10-K annual reports are available from 2009 through 2025.

Investors researching Astria Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
ERAS SEC Filings →DAWN SEC Filings →IOVA SEC Filings →AVBP SEC Filings →MBX SEC Filings →MGTX SEC Filings →REPL SEC Filings →DNA SEC Filings →
→ ATXS Financials→ ATXS Earnings→ ATXS Insider Trades

Frequently Asked Questions

ATXS SEC Filings · 8 questions

Astria Therapeutics, Inc. (ATXS) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 628 filings and access original documents at no cost. Astria Therapeutics, Inc.'s CIK is 0001454789.

ATXS SEC filingsAstria Therapeutics, Inc. SEC documentsfind ATXS 10-K